Avecho Biotechnology (ASX:AVE) EV-to-EBITDA : -2.27 (As of Apr. 26, 2024)

View and export this data going back to 1993. Start your Free Trial

What is Avecho Biotechnology EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Avecho Biotechnology's enterprise value is A$7.35 Mil. Avecho Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-3.24 Mil. Therefore, Avecho Biotechnology's EV-to-EBITDA for today is -2.27.

The historical rank and industry rank for Avecho Biotechnology's EV-to-EBITDA or its related term are showing as below:

ASX:AVE' s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.38 Med: -1.34 Max: 27.61
Current: -2.27

During the past 13 years, the highest EV-to-EBITDA of Avecho Biotechnology was 27.61. The lowest was -13.38. And the median was -1.34.

ASX:AVE's EV-to-EBITDA is ranked worse than
100% of 470 companies
in the Biotechnology industry
Industry Median: 9.14 vs ASX:AVE: -2.27

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-26), Avecho Biotechnology's stock price is A$0.004. Avecho Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.001. Therefore, Avecho Biotechnology's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Avecho Biotechnology EV-to-EBITDA Historical Data

The historical data trend for Avecho Biotechnology's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avecho Biotechnology EV-to-EBITDA Chart

Avecho Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBITDA

Get a 7-Day Free Trial

2.07

-21.35

-8.18

-12.51

-1.78

Avecho Biotechnology Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBITDA	Get a 7-Day Free Trial															-8.18	-	-12.51	-	-1.78

Competitive Comparison of Avecho Biotechnology's EV-to-EBITDA

For the Biotechnology subindustry, Avecho Biotechnology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avecho Biotechnology's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Avecho Biotechnology's EV-to-EBITDA falls into.

Avecho Biotechnology EV-to-EBITDA Calculation

Avecho Biotechnology's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	7.348	/	-3.243
	=	-2.27

Avecho Biotechnology's current Enterprise Value is A$7.35 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Avecho Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-3.24 Mil.

Avecho Biotechnology (ASX:AVE) EV-to-EBITDA Explanation

Avecho Biotechnology's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.004	/	-0.001
	=	At Loss

Avecho Biotechnology's share price for today is A$0.004.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Avecho Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.001.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Avecho Biotechnology EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Avecho Biotechnology's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Avecho Biotechnology (ASX:AVE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avecho Biotechnology Ltd (ASX:AVE) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

OEZ:Germany

Address

Unit A8, 2A Westall Road, Clayton, Melbourne, VIC, AUS, 3168

Website

https://www.avecho.com.au

Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sale, and licensing of products incorporating its patented platform technology TPM, for the pharmaceutical, skincare and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.

Avecho Biotechnology (ASX:AVE) Headlines

No Headlines